YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF‐κB signalling pathways via inhibiting EPHB3 and TNFAIP3

OBJECTIVES: Temozolomide (TMZ) resistance is a key factor that restricts the therapeutic effect of glioblastoma (GBM). YTH‐domain family member 2 (YTHDF2) is highly expressed in GBM tissues, while the mechanism of YTHDF2 in TMZ resistance in GBM remains not fully elucidated. METHODS: The YTHDF2 expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu, Wang, Yan‐Lan, Qiu, Kai, Cao, Yi‐Qiang, Zhang, Feng‐Jiang, Zhao, Hai‐Biao, Liu, Xian‐Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082891/
https://www.ncbi.nlm.nih.gov/pubmed/35582627
http://dx.doi.org/10.1002/cti2.1393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082891/
https://www.ncbi.nlm.nih.gov/pubmed/35582627
http://dx.doi.org/10.1002/cti2.1393

Ejemplares similares